Work

Exploiting LY3009120 and Asciminib Combination to Target TKI-Resistant CML

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-153353

Authors: Milad Rouhimoghadam, Anthony D. Pomicter, Alexandria Van Scoyk, Greg Poffenberger, Ivaylo Kirov, Lyubomir G. Nashev, Helong Zhao, Martin Martinov, Michael W. Deininger

Institutions: Huntsman Cancer Institute, University of Utah

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213163183

Cites:

Cited by: 3

Related to: 10